Qiagen
JP Morgan Healthcare Conference Day 1: Qiagen, Adaptive Bio, Guardant Health, Natera, Sema4
Highlights of the first day included Qiagen's strategy in the face of the COVID-19 pandemic and Adaptive Bio's development of its two major businesses.
In Brief This Week: Qiagen, Cue Health, Co-Diagnostics, Vela Diagnostics, and More
News items for the in vitro diagnostics industry for the week of Jan. 3, 2022.
Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment
The test will identify patients expressing a genomic biomarker who are likely to respond to Denovo's investigational DB102 treatment for diffuse large B-cell lymphoma.
Qiagen Obtains CE Mark for Assay Measuring T-Cell Response to SARS-CoV-2
Qiagen said its IGRA T-cell test can contribute insights into the immune response to a SARS-CoV-2 infection that go beyond what serology testing alone can provide.
Qiagen Sued for Allegedly Infringing Patent With Wi-Fi-Connected Instrument
The plaintiff has sued at least 10 other companies for infringing the patent, which relates to connecting a device to a communication network.